A computational chemistry study in JCIM volume 66, issue 17 targets a protein interaction with designed peptide inhibitors.
Recap by typeshit. Post by JCIM & JCTC Journals on X.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Roche is betting on ALK7, a target that could in theory cut fat while sparing lean mass. Arrowhead, Alnylam, GSK and Novo are chasing it too.
The surgeon flags risks he sees in using the so-called Barbie peptide for tanning, saying men in particular should be careful.
Loading…